<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Transcatheter <z:hpo ids='HP_0001655'>patent foramen ovale</z:hpo> (<z:mp ids='MP_0004225'>PFO</z:mp>) closure might be effective in improving <z:hpo ids='HP_0002076'>migraines</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>To assess the efficacy of <z:mp ids='MP_0004225'>PFO</z:mp> closure in migraineurs with a moderate to large <z:hpo ids='HP_0001694'>right-to-left shunt</z:hpo> and instrumental evidence of embolic cerebral damage, 76 highly symptomatic migraineurs were prospectively investigated </plain></SENT>
<SENT sid="2" pm="."><plain>The presenting clinical syndrome was <z:hpo ids='HP_0001297'>stroke</z:hpo> in 16 patients, repeated <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> in 32 patients, and lone <z:hpo ids='HP_0002076'>migraine</z:hpo> associated with cerebral ischemic lesions on magnetic resonance imaging in 28 patients </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0002076'>Migraine</z:hpo> severity was assessed before <z:mp ids='MP_0004225'>PFO</z:mp> closure and monthly for 6 months after discontinuation of antiplatelet therapy </plain></SENT>
<SENT sid="4" pm="."><plain>At the end of 12 months of follow-up, the averaged postprocedural total score was compared with the baseline score </plain></SENT>
<SENT sid="5" pm="."><plain>Transcatheter <z:mp ids='MP_0004225'>PFO</z:mp> closure was successful in <z:hpo ids='HP_0000001'>all</z:hpo> patients, and the 12-month <z:mp ids='MP_0004225'>PFO</z:mp> closure rate was 97% </plain></SENT>
<SENT sid="6" pm="."><plain>The baseline total <z:hpo ids='HP_0002076'>migraine</z:hpo> score was similar in patients with <z:hpo ids='HP_0001297'>stroke</z:hpo>, <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo>, and lone <z:hpo ids='HP_0002076'>migraine</z:hpo> (6.8 +/- 1.6, 6.7 +/- 1.4, and 6.9 +/- 1.7 respectively, p = NS) </plain></SENT>
<SENT sid="7" pm="."><plain>After a mean follow-up of 13.7 +/- 2.4 months, no recurrent cerebrovascular episodes had occurred </plain></SENT>
<SENT sid="8" pm="."><plain>At the end of the follow-up period, a significant reduction in the total <z:hpo ids='HP_0002076'>migraine</z:hpo> score was observed in <z:hpo ids='HP_0000001'>all</z:hpo> groups, regardless of the initial clinical presentation </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0002076'>Migraine</z:hpo> was completely abolished in 35 patients (46%), improved in 27 (36%), and unchanged in 14 (18%) </plain></SENT>
<SENT sid="10" pm="."><plain>The proportion of patients with <z:hpo ids='HP_0002076'>migraine</z:hpo> suppression and improvement was similar in the 3 groups </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, in highly symptomatic migraineurs with previous ischemic cerebral events and instrumental evidence of <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e>, transcatheter <z:mp ids='MP_0004225'>PFO</z:mp> closure can result in improvement of <z:hpo ids='HP_0002076'>migraine</z:hpo> severity in a high percentage of patients </plain></SENT>
</text></document>